Skip to content
6-K

Foreign Interim / Material

COSCIENS Biopharma Inc. CSCIF

0001493152-25-021774

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q3 2025 · Sep 30, 2025 3.18M sh
Shares Diluted Q3 2025 · Sep 30, 2025 3.16M sh
Shares Diluted Q3 2025 · Sep 30, 2024 3.11M sh
Shares Diluted Q3 2025 · Sep 30, 2024 2.39M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$676K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$7M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$7.78M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$11.57M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $8.52M
Cash And Equivalents Q3 2025 · Jun 30, 2025 $9.33M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $16.39M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $20M
Cash And Equivalents Q3 2025 · Jun 30, 2024 $27.8M
Cash And Equivalents Q3 2025 · Dec 31, 2023 $6.68M
Current Liabilities Q3 2025 · Sep 30, 2025 $3.98M
Current Liabilities Q3 2025 · Dec 31, 2024 $7.21M
Total Liabilities Q3 2025 · Sep 30, 2025 $18.78M
Total Liabilities Q3 2025 · Dec 31, 2024 $21.91M
Current Assets Q3 2025 · Sep 30, 2025 $13.84M
Current Assets Q3 2025 · Dec 31, 2024 $23.98M
Total Assets Q3 2025 · Sep 30, 2025 $23.86M
Total Assets Q3 2025 · Dec 31, 2024 $35.07M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.57
Eps Diluted Q3 2025 · Sep 30, 2025 −$2.59
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.85
Eps Diluted Q3 2025 · Sep 30, 2024 −$3.58
Eps Basic Q3 2025 · Sep 30, 2025 −$0.57
Eps Basic Q3 2025 · Sep 30, 2025 −$2.59
Eps Basic Q3 2025 · Sep 30, 2024 −$1.85
Eps Basic Q3 2025 · Sep 30, 2024 −$3.58
Sga Expense Q3 2025 · Sep 30, 2025 $2.1M
Sga Expense Q3 2025 · Sep 30, 2025 $7.66M
Sga Expense Q3 2025 · Sep 30, 2024 $2.99M
Sga Expense Q3 2025 · Sep 30, 2024 $7.7M
Rd Expense Q3 2025 · Sep 30, 2025 $527K
Rd Expense Q3 2025 · Sep 30, 2025 $2.35M
Rd Expense Q3 2025 · Sep 30, 2024 $2.8M
Rd Expense Q3 2025 · Sep 30, 2024 $5.39M
Net Income Q3 2025 · Sep 30, 2025 −$1.82M
Net Income Q3 2025 · Sep 30, 2025 −$8.18M
Net Income Q3 2025 · Sep 30, 2024 −$5.76M
Net Income Q3 2025 · Sep 30, 2024 −$8.58M
Operating Income Q3 2025 · Sep 30, 2025 −$2.32M
Operating Income Q3 2025 · Sep 30, 2025 −$8.29M
Operating Income Q3 2025 · Sep 30, 2024 −$6.29M
Operating Income Q3 2025 · Sep 30, 2024 −$11.87M
Gross Profit Q3 2025 · Sep 30, 2025 $621K
Gross Profit Q3 2025 · Sep 30, 2025 $2.04M
Gross Profit Q3 2025 · Sep 30, 2024 $957K
Gross Profit Q3 2025 · Sep 30, 2024 $2.68M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $862K
Cost Of Revenue Q3 2025 · Sep 30, 2025 $3.69M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $914K
Cost Of Revenue Q3 2025 · Sep 30, 2024 $3.59M
Revenue Q3 2025 · Sep 30, 2025 $1.48M
Revenue Q3 2025 · Sep 30, 2025 $5.73M
Revenue Q3 2025 · Sep 30, 2024 $1.87M
Revenue Q3 2025 · Sep 30, 2024 $6.27M